×
Back to Agenda
The Development of Novel Digital Endpoints
Session Chair(s)
Michelle Crouthamel, PHD
Head, Digital Science, AbbVie, United States
This session will be used to present two examples of novel digital endpoint development with live chat and Q&A discussion to follow.
Learning Objective : Discuss the novel digital development framework through industry examples; Identify the concept of interest, the context of use, and the design of validation will be included.
Speaker(s)
Itching for Feedback: Framework for Qualifying Novel Digital Outcomes
Executive Director, Early Clinical Development, Pfizer Inc, United States
The Development of Novel Digital Endpoints
Director, Clinical Outcomes - Assessments and Innovation, Regeneron Pharmaceuticals, United States
The Development of Novel Digital Endpoints
Director, Precision Medicine Quantitative Translational Sciences, Regeneron, United States
Have an account?